ArticleFrontiers in pharmacology2022

Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China.

Dongchu Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.